Helicobacter pylori vaccine development: optimisation of strategies and importance of challenging strain and animal model.
Gastric infection with the gram-negative bacterial pathogen Helicobacter pylori is widespread (approximately 50% of the human population is affected) and is associated with the induction of specific gastroduodenal disease. Although extensive studies in the H. pylori mouse model have demonstrated the feasibility of both therapeutic and prophylactic immunisations, the mechanism of vaccine-induced protection is still poorly understood. We report here on novel strategies to optimise the generation of H. pylori ghosts as vaccine candidates and highlight the need to concentrate on alternative animal models and the use of fully virulent H. pylori type I strains for vaccination. An effective vaccine strategy against H. pylori has the potential to significantly improve population health worldwide.
Hoffelner
Herbert
H
Max von Pettenkofer Institut für Hygiene und Medizinische Mikrobiologie, LMU München, Pettenkoferstrasse 9a, D-80336 München, Germany.
Rieder
Gabriele
G
Haas
Rainer
R
D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology*; D004195:Disease Models, Animal; D005767:Gastrointestinal Diseases / Q000276:immunology / Q000382:microbiology* / Q000517:prevention & control; D016481:Helicobacter Infections / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D007114:Immunization / Q000379:methods
D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; C074689:VacA protein, Helicobacter pylori; C080866:cagA protein, Helicobacter pylori